Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Non Operating Income (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Non Operating Income for 6 consecutive years, with -$2.7 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 44.2% to -$2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.2 million through Dec 2025, down 124.07% year-over-year, with the annual reading at -$5.0 million for FY2025, 207.46% down from the prior year.
  • Non Operating Income hit -$2.7 million in Q4 2025 for Lyell Immunopharma, up from -$4.9 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $10.0 million in Q4 2023 to a low of -$36.2 million in Q4 2021.
  • Historically, Non Operating Income has averaged -$744550.0 across 5 years, with a median of $224000.0 in 2021.
  • Biggest five-year swings in Non Operating Income: skyrocketed 1854.29% in 2024 and later tumbled 11200.0% in 2025.
  • Year by year, Non Operating Income stood at -$36.2 million in 2021, then soared by 113.79% to $5.0 million in 2022, then surged by 101.0% to $10.0 million in 2023, then tumbled by 118.51% to -$1.9 million in 2024, then tumbled by 44.2% to -$2.7 million in 2025.
  • Business Quant data shows Non Operating Income for LYEL at -$2.7 million in Q4 2025, -$4.9 million in Q3 2025, and $1.2 million in Q2 2025.